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CHEMOTHERAPEUTIC AGENTS currently
used for antitumour therapy are selected
for their toxicity towards rapidly pro-
liferating cells. Most of them cause un-
desirable systemic effects such as cardiac
or renal toxicity, marrow aplasia, alopecia,
nausea and vomiting. During the last few
years many authors have tried to eliminate
these side effects by increasing the avail-
ability of the drug to the tumour site.
Enzymes, radioisotopes, DNA, toxins,
various macromolecules, and antibodies
against fibrin or against tumour-specific
surface antigens were bound to drugs in an
attempt to increase the selectivity of the
chemotherapeutic agents, or to decrease
their toxic effects on normal cells (Rubens,
1-974; Gregoriadis, 1977).
The targeting ofdrugs to the tumour by
antibodies to surface antigens may have
considerable implications by increasing
the therapeutic index. This approach,
although promising in an animal system,
could hardly be used for human treatment,
since it would require antibodies raised
against each patient's tumour extract,
followed by exhaustive absorptions with
normal human tissues. On the other hand,
human tumours often produce oncofoetal
proteins such as carcinoembryonic antigen
and alphafoetoprotein which are expressed
in a wide variety of tumours, and are also
used as markers in the follow-up of
patients (Gold & Freedman, 1965; Sell
& Becker, 1978). Antibodies against these
oncofoetal antigens might be good candi-
dates as carriers of chemotherapeutic
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agents to the cancer cells producing
oncofoetal markers.
Our study is an in vitro evaluation of
the efficiency of this new approach of
immunochemotherapy. We have used the
anthracycline Daunomycin (Rhone-
Poulenc) covalently bound to anti-alpha-
foetoprotein (anti-AFP) immunoglobulins
as specific carriers to the BW-7756 mouse
hepatoma cells producing AFP. Binding
was performed in the presence of glutar-
aldehyde, and the protein fraction was
subsequently separated from the free drug
by chromatography on Sephadex G-25
(Pharmacia Fine Chemicals)(Hurwitz etal.,
1975). The binding ratio used in the experi-
ments was about 4 mol of drug per mol of
protein, and the concentration of drug
was 0 5 ig/ml of culture medium.
Fig. 1 shows that when 3 x 103 hepatoma
cells are incubated with the conjugate for
short periods of time, washed and re-
incubated in fresh culture medium for a
long-term culture, they lose their ability
to proliferate and form colonies. This
drastic effect is observed with the con-
jugate within 6 h as compared to a 1-day
incubation to obtain the same effect with
the drug alone or with the physical mix-
ture of the drug and the antibody. This
points to the specificity of the conjugate
and its rapid adherence on to the cells.
Fig. 2 presents the dose-response rela-
tionships obtained with the BW hepatoma
cells treated respectively with 0, 0-1, 0-5
and 1-0 ,ug of Daunomycin/ml culture
medium. A slight synergistic effect was842 M. BELLES-ISLES AND M. PAGE
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FIG. 1.-Antimitotic activity. 3 x 103 BW-
7756 cells were treated for short incubation
periods, washed and reincubated for 5 days
in fresh culture medium. *, Ab, anti-AFP
antibody; A, D, daunomycin; 0, D-Ab,
conjugate. Q, Control; A, D+Ab.
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FIG. 2.-Dose-response relationship. 2x 103
cells were treated with increasing concen-
tration of Daunomycin free (D), covalently
bound (D-Ab) or mixed (D+Ab) to anti-
AFP immunoglobulins.
seen with the physical mixture ofthe drug
and the antibody. For any concentration
of drug used, the greatest cell killing was
found with the use of the Daunomycin-
anti-AFP conjugate.
The Table shows that, when compared
to a nonspecific macromolecule (bovine
serum albumin) used as a carrier for the
drug, the specific antibody-Daunomycin
conjugatewasasignificantly more effective
inhibitor ofcolonyformation and [3H]TdR
TABLE.-Effects of Daunomycin, free or
covalently bound to albumin or anti-AFP
antibody on BW-7756 mouse hepatoma
cells
% Inhibition of
Colony [3H]-TdR
Treatment formation incorporation
Anti-AFP 0 0
(Anti-AFP+Dauno) 74 N.D.*
(Anti-AFP--Dauno)
conjugate 80 58
Dauno 62 21
(Albumin+Dauno) 57 N.D.
(Albumin-Dauno)
conjugate 18 4
Albumin 0 0
* N.D.: Not determined.
incorporation, thus showing the specificity
ofthe system.
Our results indicate that Daunomycin
covalently bound to specific anti-onco-
foetal protein antibodies presents a
superior antitumour activity relative to
the free drug, the free antibody, the mix-
ture of both agents or to a nonspecific
macromolecule as the carrier for the
chemotherapeutic agent. Such an in-
creased cell killing with the specific con-
jugate in these in vitro experiments was
unexpected. Our results also suggest that
the synergistic effect of the physical
mixture of the 2 substances is not the
unique process involved. The complete
mechanism is still unknown.
However, this new approach offers a
potential clinical application, since the
specificity ofthe conjugates forthe tumour
cells may reduce the systemic toxicity of
the chemotherapeutic agents. This is being
tested in vivo on tumour-bearing animals.
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